Joshua Bauml, Lung Cancer DAS Leader at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“Leaving the American Society of Clinical Oncology (ASCO) annual meeting this year, I’m reflecting on the science, the conversations, and the patients at the center of both. New data in EGFR-mutated non-small cell lung cancer, and advanced head and neck cancer offered encouraging signs of progress in settings where unmet need remains high.
As someone who loves to run when traveling for meetings, I’ve always found that conferences like ASCO have a rhythm of their own.
There’s the early start, the steady pace, the long stretches of listening and learning, and the moments that push you to look up and think about where the field is headed. Running has taught me that progress rarely happens all at once. It comes from consistency, resilience, and the belief that even difficult miles can move you closer to something meaningful.
That’s how I’m thinking about this year’s ASCO: not as a finish line, but as another mile marker on the road ahead. We are running into the future of cancer care with more insight, more questions, and, importantly, more reason to keep going for patients.”
Other articles featuring Joshua Bauml on OncoDaily.